Aptose Biosciences Inc. (APTOF): Nasdaq/NYSE listing notice — Aptose gets Nasdaq delisting notice for low bid price; reverse split vote Jan 27

Aptose Biosciences Inc.

Received Staff letter Jan 14, 2025 for failing $1 minimum bid price for 30 consecutive days.
Must regain compliance by March 31, 2025 or present plan to hearings panel.
Special shareholders' meeting Jan 27, 2025 to approve reverse stock split.
Common shares continue to trade on TSX; unaffected by Nasdaq status.
No assurance of regaining compliance with Nasdaq listing rules.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aptose Biosciences Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is required to present its plan of comp

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Aptose Biosciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“

View on SEC.gov

Browse all listing & compliance notices →

Aptose Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-009627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.